drugset
Drugs / Aleniglipron
last change 2 days ago re-read 3 minutes ago

Aleniglipron

also known as GSBR-1290

Small molecule

Developed for
obesity disorder · type 2 diabetes mellitus
Investigated by
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Trials 9

today NCT07654361 · Ph 3 NCT07654374 · Ph 3 NCT07400588 · Ph 2 NCT07169942 · Ph 2 NCT06703021 · Ph 2 NCT06693843 · Ph 2 NCT06139055 · Ph 1 NCT05893043 · Ph 1 NCT05762471 · Ph 1/2
202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06139055 Oct 2023 → Mar 2024 — Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Unknown No outcome recorded
Phase 1 NCT05893043 Apr → Jun 2023 — Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05762471 Jan 2023 → Apr 2024 obesity disorder, type 2 diabetes mellitus Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Completed No outcome recorded
Phase 24 trials · 1 met primary
Phase 2 NCT07400588 Dec 2025 → Sep 2026 overdue obesity disorder, type 2 diabetes mellitus Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Active not recruiting No outcome recorded
Phase 2 NCT07169942 Aug 2025 → Aug 2026 overdue obesity disorder Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Active not recruiting No outcome recorded
Phase 2 NCT06703021 Dec 2024 → Jan 2026 obesity disorder Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Completed No outcome recorded
Phase 2 NCT06693843 Oct 2024 → Oct 2025 overdue obesity disorder Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Active not recruiting Met primary
Phase 32 trials
Phase 3 NCT07654361 Jul 2026 → Sep 2028 expected obesity disorder Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Not yet recruiting No outcome recorded
Phase 3 NCT07654374 Jul 2026 → Sep 2028 expected obesity disorder, type 2 diabetes mellitus Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Not yet recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Aleniglipron ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693843 ↗
5

NCT07169942 ↗

NCT07400588 ↗

NCT07654361 ↗

NCT06703021 ↗

NCT07654374 ↗
Known as GSBR-1290 “A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least...” NCT06693843 ↗
5

“A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body...” NCT07169942 ↗

“Aleniglipron (GSBR-1290)” NCT06703021 ↗

NCT05893043 ↗

NCT06139055 ↗

NCT05762471 ↗
Action Activate “glucagon-like peptide-1 receptor agonist” PMID 42249138 ↗ Jun 2026
Modality Small molecule “Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment.” PMID 42249138 ↗ Jun 2026
Route Oral “Participants will receive GSBR-1290 oral capsules.” NCT05893043 ↗